August 31, 2023
Santa Monica, CAFor Immediate Release
Contact:
Lei Peremne
Client Solutions Manager
(424) 330-2885
lei@patexia.com
Patexia Releases 2023 ANDA Litigation Intelligence Report, Showcasing Trends and Stakeholder Rankings
Santa Monica, CA (August 31, 2023): Patexia, the forefront intellectual property analytics company, proudly unveils its latest release – the 2023 ANDA Litigation Intelligence Report. This groundbreaking report delves into the realm of Hatch-Waxman case trends, providing invaluable insights into the landscape of pharmaceutical patent litigation.
ANDA litigation activity showed variations over consecutive years, dropping from 29.3 cases per month in 2018 to 20.5 in 2020, but rebounding with upward trends to 21.9 and 24.8 cases per month in 2022 and 2023, respectively. Within this comprehensive report, industry professionals and legal experts not only can explore the dynamic world of ANDA litigation, gaining access to trends, statistics, and terminated cases outcome analysis, but also access the rankings of attorneys, law firms, and companies based on their performance and activity in the brand, generic, or overall category.
Some interesting highlights from this year’s report include the following:
- During the last five years, 1,428 ANDA cases were filed by 267 brand pharmaceuticals against 265 generic pharmaceuticals.
- 1,774 unique patents were at the center of these ANDA cases
- 226 law firms represented the combined 469 pharmaceuticals either as defendants or plaintiffs.
- 1,666 ANDA attorneys acted as lead counsel for defendants or plaintiffs
- 270 attorneys acted as local counsel for plaintiffs and defendants
- Teva Pharmaceuticals was the most active company with involvement in 131 cases
- MSN Laboratories with a success rate of 100%, was the best-performing company in ANDA litigation.
Pedram Sameni, CEO of Patexia, underscores the paramount importance of this report for pharmaceutical entities and legal practitioners seeking strategic guidance in the complex realm of ANDA litigation. Notably, this year’s report introduces an exciting enhancement – the integration of Patexia attorney reviews. With an innovative chapter spotlighting top-ranked attorneys, the report now incorporates peer, in-house counsel, and opposing counsel assessments, providing a 360-degree view of attorney’s excellence. Moreover, Patexia has revolutionized its ranking methodology, integrating advanced machine learning techniques to dissect and isolate the multifaceted factors influencing the success of entities involved in ANDA litigation. This cutting-edge approach ensures unparalleled insights for decision-makers navigating the intricate landscape of pharmaceutical patent challenges.
The 2023 ANDA Litigation Intelligence Report is now available for purchase and download, offering an indispensable tool for legal professionals and stakeholders seeking to navigate the evolving landscape of ANDA litigation with confidence. Obtain your copy today at ANDA Litigation Intelligence Report | Patexia
About Patexia:
Established in 2010, Patexia is a global network for IP professionals with over 100,000 profiles. The company leverages data, technology, and experts to bring efficiency and transparency to intellectual property. Patexia offers IP services under four distinct arms: Connect (recruiting and experts), Contest (crowdsourced patent due diligence), Research (IP databases), and Insights (IP reports).
For more information, visit http://www.patexia.com/about_us.html
PEDRAM SAMENI IS AVAILABLE FOR INTERVIEW
Contact:
Lei Peremne
Client Solutions Associate
(424) 330-2885
lei@patexia.com
